Redox-responsive tumor targeted dual-drug loaded biocompatible metal–organic frameworks nanoparticles for enhancing anticancer effects

Metal–organic frameworks (MOFs) have proven to be a promising class of drug carriers due to their high porosity, crystalline properties with defined structure information, and abundant surface chemistry for further functionalization. However, there has not been extensive research on MOF-based drug carriers with stimuli-responsive, dual-drug delivery, and tumor targeting functions. Here, we demonstrate the strategy of constructing a redox responsive and tumor-targeted MOF as dual-drug carrier by anchoring functional disulfide anhydride and folic acid molecules to the organic links of MOFs, respectively. The MOF composites show the controlled release of loaded 5-fluorouracil (5-FU) entrapped within UiO-66-NH2 nanostructures modified with dichloroacetic acid, which acts as a synergistical drug to 5-FU in cancer cells. In addition, the overexpressed GSH in cancer cells attacks the thiolate moiety and is oxidized in the process as it cleaves the disulfide bonds, thereby achieving redox stimuli-responsive drugs release in MOFs. The confocal laser scanning microscopy further proved that conjugation of folic acid to the MOF surface can significantly enhance the targeting uptake of cancer cells. This work paves the way to the construction of stimuli responsive tumor-targeted Nano MOF based drug carriers with potential for cancer therapies.


Introduction
The increasing incidence and mortality of cancer over the past few decades has challenged current drug treatments. Many approaches are limited by their non-specific distribution throughout the body, resulting in needing of high amount of drug doses, rapid drug clearance, poor pharmacokinetics, and severe adverse drug effects. Although many different strategies have been developed to improve the efficacy of conventional drugs, nanoparticle-based drug delivery systems have received increasing attention over the past 20 years. By using these novel nanosystems, many of the shortcomings of small molecule drugs can be effectively alleviated [1]. Generally, nanomedicines are composed of active pharmaceutical ingredients incorporated into nanoparticle carriers. Various nanocarriers such as polymer nanoparticles [2,3], micelles [4], liposomes [5], iron oxides [6], and gold [7] have been developed and used for this purpose. The good nanocarriers have key properties including small and tunable size, high drug loading capacity and efficiency, favorable surface properties, in demand drug release kinetics, improved pharmacokinetics, and biocompatibility. Besides, nanoparticles can specifically target diseased tissues (such as tumor regions) by binding to target receptors [8], and can be engineered to enable theranostics [9], Open Access BMC Materials *Correspondence: hongbo.zhang@abo.fi 1 Pharmaceutical Sciences Laboratory and Turku Bioscience Center, Åbo Akademi University, 20520 Turku, Finland Full list of author information is available at the end of the article while are difficult to be achieved with conventional therapies. Another important part of nano-drug delivery is the stimuli responsive mechanism [10], which determines whether the drug delivery system has a controlled release function. The precise design of the controlled release behavior should be based on a thorough understanding of the relevant stimulation signals and release mechanisms in physiological and pathological conditions. Nanomedicines that respond to pH [11,12], temperature [13], light [14], redox state [15], magnetic fields [16,17], biomolecules [18], or combinations thereof have been developed and proved. The clinical success of nanoparticle-based therapy illustrates the power of this approach. Currently, many promising nanoparticles-drug combinations are at different stages of clinical development.
Metal-organic frameworks (MOFs), as a new type of porous and crystalline materials, assembled from metal ions (or metal clusters) and organic linkers, have shown various potential applications, such as adsorption of gas or water [19], catalysis [20], sensing [21], proton conduction [22], and drug delivery [23,24]. In the past few decades, nanoscale metal-organic frameworks have attracted great attention in the field of particle-mediated cancer drug delivery [25]. They have shown advantages over conventional drug carrier materials, for example, they have various morphologies with well-defined crystal structure, high surface area, large drug loading capacity, and intrinsic biodegradability caused by relatively unstable coordination bonds. Due to its hybrid nature related to organic ligands and inorganic building blocks, MOFs have tremendous opportunities for further customization and functionalization. In general, the organic components of MOFs are more concerned with the subsequent post-synthetic modification (PSM) [26], and organic molecules are covalently connected through various organic reactions, thereof providing new chemical functions for grafting of drug molecules. Through reasonable PSM, MOFs drug carriers can co-deliver two different chemical anticancer drugs and potentially stimuli-responsive release drugs to tumor cells because cancer cells have higher overexpressing reducing components than normal cells [27]. The fabrication of stimuli-responsive surfaces on MOFs for environmentally sensitive site-specific drug delivery can also reduce the risk of premature drug leakage. Although, there are reports that some targeted MOF carrier could delivery two different drugs and achieve targeting release around cancer cells due to the lower pH than normal cells, the MOF-based drug delivery system with stimuli-responsive and targeting functions has not been explored. In addition to introducing stimuli-responsive/targeting MOF hybrids as a new functional material for targeting tumor and controlled drug release, the use of MOFs also has important advantages over other stimuli-responsive porous carriers. Furthermore, the formation of the MOFs determines a uniform pore size, and therefore, it is expected that the released loads will reveal a more controlled release profile. The conjugation of anhydride acids with MOFs as stimuli-responsive capping units is particularly interesting because biological components can be used to unlock the chemical bonds of caps to achieve rapid drug release. Here, folic acid (FA) is one of the most commonly used tumor-targeting ligands in drug delivery system because folic acid receptors are well-known tumor markers and the conjugation chemistry to therapeutic agents is well characterized [28].
In this study, we report the design of redox-responsive dual-drug delivery tumor-targeted MOFs nanocarriers (Scheme 1). Here, the zirconium MOF UiO-66-NH 2 (UiO stands for Universitetet i Oslo) was selected as the model as a drug carrier [29]. During the synthesis of nanoparticles, we introduced dichloroacetic acid (DCA) as part of the organic links fused in the framework to control the size and as a second anticancer drug to enhance the cancer cell cytotoxicity of the dual-drug delivery system. The amino groups on the surface of the nanoparticles were then modified with the 3,3′-dithiodipropionic acid anhydride (DTDPA) to link with tumor-targeted components. After entrapping 5-fluorouracil (5-FU) in the DTDPAmodified MOFs, the resulting nanoparticles were then coordinated by aminated folic acid molecules to prevent drug leakage. The nanocarriers then accumulated in tumor tissues through the EPR and FA targeting effects and uptaken in cancer cells via endocytosis. Thereafter, the redox responsive disulfide bonds were broken down in the presence of overexpressed GSH. The structure of nanocarriers, on the other hand, deconstructed with the release of contained drugs, enhancing anticancer effects by synergistic of DCA and 5-FU.

Results and discussion
Dichloroacetic acid (DCA) is a pyruvate D-kinase inhibitor that is overexpressed in cancer cells. Its cytotoxic effect on cancer cells depends on effective cytoplasmic release and mitochondrial localization, making it an ideal probe molecule for cellular uptake mechanism [30]. In order to promote cytoplasmic release through passive diffusion, UiO-66-NH 2 (DCA-UiO-66-NH 2 ) doped with dichloroacetic acid (DCA) was synthesized by heating N, N'-dimethylformamide (DMF) solution in the oven at 120 °C for 24 h, containing Zr 4+ , 2-amino-1,4-benzenedicarboxylicacid (NH 2 -H 2 BDC) ligands, and dichloroacetic acid, respectively, with gently stirring. In the synthesis of the DCA-UiO-66-NH 2 , different ratios of metal ions and ligands were used to obtain the optimal nanoscale products. As a regulator of UiO-66-NH 2 solvothermal synthesis, it showed that DCA was incorporated into the defects of UiO-66-NH 2 nanoparticles and their surfaces, as shown in Additional file 1: Fig. S1. For DCA-UiO-66-NH 2 , when the molar ratio of Zr 4+ , NH 2 -H 2 BDC, and DCA was 1:1:9, the particle size of the obtained product was around 50 nm, as characterized by transmission electron microscopy (TEM) (see Additional file 1: Fig. S1a), which is superior to most MOF-based targeted drug carriers reported in the literature. In order to prove the surface chemistry and structure of the synthesized DCA-UiO-66-NH 2 , Fourier-transform infrared spectroscopy (FT-IR) and powder X-ray diffraction (PXRD) analysis were performed. The FT-IR spectra of DCA-UiO-66-NH 2 showed a new band in the carboxylic acid region but shifted compared to free DCA, which was characteristic of the carboxylic acid in DCA that connected to the Zr 6 units. The presence of a new band related to the C-Cl stretching at around 800 cm −1 was appreciable, and no shifting was observed (Additional file 1: Fig. S2). Furthermore, their PXRD patterns closely matched the simulated patterns derived from the single-crystal X-ray diffraction data, which proved the successful synthesis of the DCA-UiO-66-NH 2 (Fig. 2).
The covalent post-synthetic modification of DCA-UiO-66-NH 2 was explored by using an alkyl anhydride to produce carboxylic group terminal frameworks designated DCA-UiO-DTDP (in Additional file 1: Fig. S3). According to the previous literature in Additional file 1: Fig. S4, 3,3′-dithiodipropionic acid anhydride (DTDPA) was obtained by acylation of 3,3′-dithiodipropionic (DTDP) acid with acetyl chloride [31]. The resonance at δ = 12.35 ppm corresponded to the carboxyl proton of the DTDP, and the peak disappeared after refluxing in acetyl chloride, which indicated the successful formation of DTDPA in 1 H NMR in Additional file 1: Fig. S5. In a typical post-synthetic modification reaction, after the synthesis of DCA-UiO-66-NH 2 , 1:1 molar ratio of DTDPA was placed in the above DMF solution. After standing at room temperature for 24 h, the sample was rinsed with methanol to extract byproducts from the porous solids. The modification was confirmed by nuclear magnetic resonance (NMR) spectroscopy. The sample of post-synthetic modification treated DCA-UiO-66-NH 2 materials was digested with D 2 SO 4 and DMSO-d 6 for examination by 1 H NMR spectroscopy. The digestion of unmodified DCA-UiO-66-NH 2 mainly showed resonances related to 2-amino-1,4-benzene dicarboxylic acid, and the resonance at δ = 6.2 ppm corresponded to the -CCl 2 H proton of DCA in Additional file 1: Fig. S6. It is not possible to quantitatively determine the DCA loading value from the NMR spectra alone. However, according to the external standard method of 1 H NMR standard curve of DCA in Additional file 1: Fig. S6, from the 1 H NMR spectra of acid digested DCA-UiO-66-NH 2 samples, it was estimated that the incorporation amount of DCA was 17.96%. At the same time, some minor impurities were also observed in the aromatic region of DCA-UiO-DTDP, which seemed to be associated with the amino-functionalized benzenedicarboxylate (BDC) ligand (Additional file 1: Fig. S7). The TEM in Fig. 1b and XRD in Fig. 2 confirmed that there was no significant change in the Next, we tried to establish an active targeting model on the MOFs platform by performing post-synthetic modification on the modified surfaces of DCA-UiO-DTDP. Since there are available binding sites on the surface of DCA-UiO-DTDP, the terminal amino group of aminated folic acid (NH 2 -FA) has a great chance to be coordinated with the ligands on the surface of DCA-UiO-DTDP. Additional file 1: Fig. S8 shows the synthesis procedure of aminated folic acid between folic acid and ethylenediamine [32]. The obtained NH 2 -FA was analyzed in Additional file 1:  Fig. S10), which indicated that the reactions were successful. In contrast, the PXRD patterns of the DCA-UiO-DTDP-FA and its parent MOF did not show any differences, demonstrating the integrity of their frameworks after the reaction (Fig. 2). After the anchoring with the NH 2 -FA, a thin and uniform layer was formed on the surface of DCA-UiO-66-DTDP crystals, and its thickness was about several nanometers, as shown in Fig. 1c.
For biological applications, the biocompatibility and cytotoxicity of the anticancer drugs and prepared materials must be evaluated, and here we have used the cell proliferation assay Roche diagnostics reagent (WST-1). The cytotoxicity of the DCA-UiO-DTDP, DCA-UiO-DTDP-FA and free DCA (in the form of sodium dichloroacetate, NaDCA, eliminating cytotoxic effects caused by pH changes) were measured towards breast cancer cell line MDA-MB-231 and non-tumorigenic epithelial cell line MCF-10A. The WST-1 assay results for NaDCA are shown in Additional file 1: Fig. S11, confirming that DCA has little effect on cell proliferation due to its natural hydrophilic properties leading to poor internalization, and a decrease in cell viability was observed only at concentrations higher than 2 mg/mL, with 69.5 ± 9.9% and 91.0 ± 12.6% viabilities after incubation of NaDCA in MDA-MB-231 and MCF-10A, respectively. Then, the cell viability was measured by the WST-1 assay for 72 h with different concentrations of the DCA-UiO-DTDP and DCA-UiO-DTDP-FA (10, 20, 50, 100, 200, 500, and 1000 μg/ mL). As can be seen from Additional file 1: Fig. S12, even at concentrations as high as 1000 μg/mL, the samples showed high viability over the entire concentration range. When MDA-MB-231 cancer cells were incubated with various concentrations of DCA-UiO-DTDP and DCA-UiO-DTDP-FA, the nanocomposites showed little toxicity to concentrations up to 500 μg/ mL, and cell viability was about 80%, even with the active targeting capability of DCA-UiO-DTDP-FA.  Moreover, the incubation of DCA-UiO-DTDP and DCA-UiO-DTDP-FA with MCF-10A cells revealed that the DCA-UiO-DTDP-FA had no effect on normal cell proliferation in vitro. These data demonstrate that DCA-UiO-DTDP-FA shows excellent biocompatibility in vitro.
According to the report, DCA can enhance the cytotoxic activity of anticancer drugs such as 5-fluorouracil (5-FU) and reducing the drug resistance of cancer cells. We selected 5-FU as a typical anticancer drug to evaluate drug loading and release behaviors and the enhanced cytotoxicity ability of 5-FU-DCA-UiO-DTDP-FA. DCA-UiO-DTDP-FA and 5-FU were used for drug loading experiments in an excess of 5-FU in methanol, and the concentration of 5-FU was measured after various concentration ratios between nanoparticles and drug (see Additional file 1: Table S1). The UV/Vis absorbance of the solution was measured at regular interval to determine the amount of loading of 5-FU on the DCA-UiO-DTDP-FA based on the UV/Vis absorbance and the standard absorbance curve of 5-FU in Additional file 1: Fig. S13. The results of the 5-FU loading experiments confirmed that the loading efficiency of DCA-UiO-DTDP-FA reached 31.6 wt% after 24 h.
The release of 5-FU from the 5-FU-DCA-UiO-DTDP-FA nanoparticles was investigated in the presence of dithiothreitol (DTT, a reducing agent that mimics the action of GSH, which is in the microenvironment of cancer cells provides a reducing environment.). It was assumed that the release of 5-FU from the nanoparticles occurs due to the breakage of disulfide bonds. DTDPA modified DCA-UiO-66-NH2 nanoparticles can form disulfide bonds with organic ligands on the surface of the nanoparticles, and then coordinate with NH 2 -FA to limit drug leakage as a gate. GSH and its oxidized form (GSSG) are responsible for the formation of intracellular redox buffer [33]. Intracellular GSH attacks the thiolate moiety and is oxidized in the process as it cleaves the existing disulfide bonds. The encapsulation and release of the drug from the DCA-UiO-DTDP-FA were investigated at 37 °C with or without DTT. As shown in Fig. 3a, the release curve indicates that about 80% of 5-FU was released from the nanoparticles after 24 h in the presence of 10 mM DTT. This result was attributed to the higher number of disulfide bonds that were cleaved in the presence of high concentration of DTT. Compared to the control experiment without DTT, limited drug was released within 24 h. The results showed that 5-FU was rapidly released from the nanoparticles in excess of DTT, mimicking the GSH present in cancer cells and the stability in plasma. The above results are of great significance to anticancer drug delivery systems based on post-synthetic modified stimuli-responsive MOFs nanoparticles.
Free 5-FU itself has significant dose-responsive cytotoxic behavior not only on cancer cells but also on normal cells (in Fig. 3b and Additional file 1: S14), but the cytotoxicity of the 5-FU-DCA-UiO-DTDP-FA samples showed higher toxicity to MDA-MB-231 cancer cells compared to 5-FU at same concentration in Fig. 3b. This may be the result of more efficient cell internalization of the nanoparticles with FA conjugation, or the DCA in the MOF structure had synergistic effect with 5-FU. To confirm this, we incubated the cells with 5-FU and NaDCA pure drugs mixed solution. Interestingly, the addition of DCA had enhanced the 5-FU effect, while the pure drug combination was still less efficiency comparing to In the case of MCF-10A cell, as shown in Additional file 1: Fig. S14, the nanoparticles had limited cytotoxicity, which proved its selectivity towards cancer cells to normal cells.
To access the cellular uptake of DCA-UiO-DTDP-FA and DCA-UiO-DTDP, confocal laser scanning microscopy (CLSM) images were recorded for MDA-MB-231 cancer cells and MCF-10A cells incubated with the nanocomposites for 1, 6, and 16 h at 37 °C respectively, as shown in Figs. 4 and 6. For each figure, the cell nucleus is stained with 4′,6-diamidino-2-phenylindole (DAPI), emits blue fluorescence, the DCA-UiO-DTDP-FA and DCA-UiO-DTDP was labeled with Sulfo-Cyanine5.5 NHS ester (Sulfo-Cy5.5) that has red fluorescence. In Fig. 4a, almost no red emission was observed in the first 1-6 h, which indicated that very few DCA-UiO-DTDP-FA nanoparticles were phagocytized by MDA-MB-231 cancer cells. The same results were also shown in the DCA-UiO-DTDP nanoparticles group in Fig. 4b. However, when the incubation time was extended to 16 h, compared with the same time in Fig. 4b, much stronger Sulfo-Cy5.5 red fluorescence emission was observed in the cytoplasm and cell nucleus in DCA-UiO-DTDP-FA group (Fig. 4a) comparing to DCA-UiO-DTDP group, which indicated that more NH 2 -FA-modified nanoparticles were uptaken by MDA-MB-231 cancer cells. The same results can also be seen from the mean fluorescent intensity (MFI) of the different cellular populations treated with different groups (Fig. 5). The MFI of the DCA-UiO-DTDP-FA group increased significantly, which was much higher than that of the DCA-UiO-DTDP group. Meanwhile, no significant red emission was observed during the entire uptaking process in MCF-10 cells (Fig. 6), which means that the two types of nanoparticles were indiscriminately consumed by normal cells and the passive uptake of normal cells was also less active than cancer cells. These results confirm that the prepared nanoparticles can be effectively phagocytized by MDA-MB-231 cancer cells through receptor-mediated endocytosis, thereby achieving the tumor cells targeting.

Conclusion
In this work, by incorporating DCA at defect sites of UiO-66-NH 2 , we have produced a MOF with high drug loading capacity. Then, we carried out two post-synthetic modification steps to functionalize the MOF with redox stimuli-responsive and tumor targeting through anchoring functional FA molecules to the disulfide bond anhydrate modified surface of MOFs. By using the anticancer drug 5-FU as the model drug, the drug showed redox responsive release, which is relevant to cancer

Synthesis of DCA-UiO-66-NH 2
Following these general steps to prepare DCA-UiO-66-NH 2 nanoparticles: in separate vessels, ZrCl 4 (1.0 g, 4.2 mmol) and H 2 BDC-NH 2 (761.0 mg, 4.2 mmol) were dissolved in 150 mL of DMF. After mixing both precursor solutions transferring into a 250 mL vial, dichloroacetic acid (DCA, 3.0 mL, 36.0 mmol) was added to the reaction mixture, after gently stirring, it was placed in the oven at 120 °C for 24 h. After cooling to room temperature, the powders were collected by centrifugation and washed 3 times with DMF and 3 times with ethanol by dispersion centrifugation cycles. The resulting MOFs were dried under vacuum for at least 12 h before analysis.

Synthesis of 3,3′-dithiodipropionic anhydride (DTDPA)
1.0 g of 3,3′-dithiodipropionic acid (DTDP) was added to 5.0 mL of acetyl chloride and refluxed at 65 °C for 2 h. The resulting solution was cooled to room temperature and the solvent was evaporated. The residue was then precipitated in diethyl ether and washed repeatedly with diethyl ether. The product 3,3′-dithiodipropionic anhydride (DTDPA) was dried in a vacuum desiccator overnight and used directly in the next step.

Postsynthetic modification of DCA-UiO-66-NH 2 by using DTDPA (as DCA-UiO-DTDP)
The amine functional groups of the MOF reacted with DTDPA to form carboxylic acid-functionalized DCA-UiO-DTDP. In a typical post-synthetic modification reaction, after synthesizing of DCA-UiO-66-NH 2 (ca. 4.0 mmol of -NH 2 ), about 4.0 mmol of DTDPA (192.25 mg) was placed in the above DMF solution. After the sample was left at room temperature for 24 h, the solution was decanted, and the crystals were washed with fresh DMF and ethanol (3 × 5 mL) and then dried under vacuum.

Synthesis of aminated folic acid
For amination, folic acid (1.0 mmol) dissolved in 30.0 ml DMSO with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 1.2 mmol) and N-Hydroxysuccinimide (NHS, 2 mmol) was reacted at 50 °C for 6 h. The obtained folic acid-NHS was mixed with ethylenediamine (10.0 mmol) and 500.0 μg pyridine and allowed to react at room temperature overnight. The crude product was precipitated by adding an excess of acetonitrile, filtered and washed three times with diethyl ether, and then dried under vacuum.

Preparation of 5-FU-loaded DCA-UiO-DTDP
Fresh DCA-UiO-DTDP was immersed in methanol for 24 h, and then the extract was discarded. Fresh methanol was then added, and the sample was immersed for another 24 h to remove H 2 O and DMF. The sample was then treated with dichloromethane to remove methanol solvates using the same procedures. After dichloromethane was removed by decantation, the sample was activated by using a dynamic vacuum at 100 °C for 12 h. To load 5-FU into the pores of DCA-UiO-DTDP, dehydrated DCA-UiO-DTDP (5 mg) was dispersed in a 5-FU containing MeOH solution (5 mL) and stirred for 1 day to yield a uniform light-yellow solution. The 5-FU-DCA-UiO-DTDP was collected by centrifugation (13,000 rpm for 10 min) and washed with MeOH (× 2) by dispersive centrifugation cycles to ensure that no residual 5-FU remained on the particle surfaces. The resulting MOFs were dried under vacuum at least 24 h before analysis. The amount of 5-FU adsorption in the porous solids was estimated by UV-Vis. The wavelength used for 5-FU quantification was 266 nm.

Fabrication of 5-FU-DCA-UiO-DTDP-FA
Same as encapsulating 5-FU in DCA-UiO-DTDP, dehydrated DCA-UiO-DTDP (5 mg) was dispersed in a 5-FU MeOH solution (3 mg/mL, 5 mL) and stirred for 1 day to yield a homogenous light-yellow solution. Then according to the ration 1:1.2:2, EDC and NHS were added to activate the carboxyl groups of DCA-UiO-DTDP. After 6 h, 5 mg of aminated FA was added to the solution. 5-FU-DCA-UiO-DTDP-FA were collected by centrifugation (12,000 r/min for 20 min) and washed with MeOH (x2) by dispersive centrifugation cycles to ensure that there is no residual 5-FU on the particle surfaces. The resulting MOFs were dried under vacuum at least 24 h before analysis. The amount of 5-FU adsorption in the porous solids was estimated by UV-Vis. The wavelengths used for 5-FU quantification was 266 nm.

In vitro drug release kinetics
The cumulative levels of 5-FU released from 5-FU-DCA-UiO-DTDP-FA nanoparticles were characterized using the dialysis method. Briefly, 15 mg of drug-loaded 5-FU-DCA-UiO-DTDP-FA was dispersed in 1.5 mL of PBS buffer solution (pH 7.4), and placed in a dialysis bag (MWCO = 500D), and then immersed in 50 mL of PBS with or without DTT (10 mM), and resuspended in a 37 °C constant temperature water bath with horizontal shaking. Here, DTT was used as a reducing agent that mimics the action of GSH, which provides a reducing environment in the microenvironment of cancer cells. At each time interval, 1 mL of the incubation solution was taken out and replenished with an equal volume of corresponding PBS. The content of 5-FU in the removed sample was monitored by HPLC, where the detection wavelength was 265 nm. The flow rate of the mobile phase was 1.0 mL/min, and the temperature was set at 30 °C. As blank controls, only eight wells were left with culture, and then DMSO (10.0 μL) was added to each well. Subsequently, WST-1 cell proliferation assay solution (10.0 μL) was added to each well, and then incubated at 37 °C for another 2 h. Finally, the absorbances of the solutions at 490 nm were measured by using a microplate reader.

Detection of cellular uptake and kinetics using confocal analysis
Cellular uptake: The cellular uptake of breast cancer cell line MDA-MB-231 and non-tumorigenic epithelial cell line MCF-10A were measured by confocal laser scanning microscopy (CLSM). Generally, MDA-MB-231 and MCF-10A cells (2 × 10 5 per well) were first seeded in confocal dishes and grown for 12 h before the uptake study, and then incubated with the prepared DCA-UiO-DTDP and DCA-UiO-DTDP-FA suspensions (2 mL, 500 mg/mL) at 37 °C for different times (1, 6 and 16 h). At different time points, the cells were washed three times with PBS. Thereafter, the cells were fixed with 4% paraformaldehyde (2 mL/well) at 37 °C for 10 min and further rinsed three times with PBS. For nucleus labeling, the nucleus were stained with DAPI solution (20 mg/ mL in PBS, 1 mL/well) for 5 min, and the cells were then washed three times with PBS again, and the samples were examined with a Zeiss LSM880 with air scan instrument.

Flow cytometric detection of cellular uptake and kinetics
The cellular uptake kinetics was studied using flow cytometer. 1-5 × 10 5 density of breast cancer cell line MDA-MB-231 and non-tumorigenic epithelial cell line MCF-10A were detached using trypsin and resuspended in 2.00 mL cell culture serum-free media containing DCA-UiO-DTDP and DCA-UiO-DTDP-FA at the concentration 500 mg/mL at different periods up to 24 h. After incubation at 37 °C cells suspension was diluted with 2 mL of PBS and centrifuged at 800 × g. The cell pellet was washed twice with PBS by centrifugation and resuspended in 500 µL of serum-free media. Fluorescence analysis was performed with BD LSRFORTESSA using Alexa Fluor 700-A channels and a 640 nm emission filter.